Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 6
Submit an article Journal homepage
1,836
Views
1
CrossRef citations to date
0
Altmetric
Coronavirus – Research Article

Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial

Ahmet Ommaa Clinic of Rheumatology, Ankara City Hospital, Ankara, TürkiyeCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2582-7445View further author information
ORCID Icon,
Ayse Batirelb Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, International Medical School, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, TürkiyeORCID Iconhttps://orcid.org/0000-0002-6005-636XView further author information
ORCID Icon,
Mehtap Aydinc Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, TürkiyeORCID Iconhttps://orcid.org/0000-0003-4044-9366View further author information
ORCID Icon,
Fatma Yilmaz Karadagd Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Istanbul, TürkiyeORCID Iconhttps://orcid.org/0000-0003-4657-5291View further author information
ORCID Icon,
Abdulsamet Erdena Clinic of Rheumatology, Ankara City Hospital, Ankara, TürkiyeORCID Iconhttps://orcid.org/0000-0002-8084-2018View further author information
ORCID Icon,
Orhan Kucuksahine Department of Internal Medicine, Division of Rheumatology, Yıldırım Beyazıt University School of Medicine, Ankara, TürkiyeORCID Iconhttps://orcid.org/0000-0003-4530-2304View further author information
ORCID Icon,
Berkan Armagana Clinic of Rheumatology, Ankara City Hospital, Ankara, TürkiyeORCID Iconhttps://orcid.org/0000-0003-4409-059XView further author information
ORCID Icon,
Serdar Can Güvena Clinic of Rheumatology, Ankara City Hospital, Ankara, TürkiyeORCID Iconhttps://orcid.org/0000-0003-1965-9756View further author information
ORCID Icon,
Ozlem Karakasa Clinic of Rheumatology, Ankara City Hospital, Ankara, TürkiyeORCID Iconhttps://orcid.org/0000-0002-3031-3353View further author information
ORCID Icon,
Selim Gokdemirf Department of Clinical Pharmacology, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, TürkiyeORCID Iconhttps://orcid.org/0000-0003-4551-3013View further author information
ORCID Icon,
Lutfiye Nilsun Altunalc Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, TürkiyeORCID Iconhttps://orcid.org/0000-0003-4794-9283View further author information
ORCID Icon,
Aslihan Ayse Buberd Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Istanbul, TürkiyeORCID Iconhttps://orcid.org/0000-0003-3518-7058View further author information
ORCID Icon,
Emin Gemcioglug Department of Internal Medicine, University of Health Sciences Ankara City Hospital, Ankara, TürkiyeORCID Iconhttps://orcid.org/0000-0001-9751-8452View further author information
ORCID Icon,
Oguzhan Zenging Department of Internal Medicine, University of Health Sciences Ankara City Hospital, Ankara, TürkiyeORCID Iconhttps://orcid.org/0000-0001-6575-4450View further author information
ORCID Icon,
Osman Inang Department of Internal Medicine, University of Health Sciences Ankara City Hospital, Ankara, TürkiyeORCID Iconhttps://orcid.org/0000-0002-8717-3013View further author information
ORCID Icon,
Enes Seyda Sahinerg Department of Internal Medicine, University of Health Sciences Ankara City Hospital, Ankara, TürkiyeORCID Iconhttps://orcid.org/0000-0003-4552-0387View further author information
ORCID Icon,
Gulay Korukluogluh National Virology Reference Laboratory, General Directorate of Public Health, Ankara, TürkiyeORCID Iconhttps://orcid.org/0000-0001-7625-6350View further author information
ORCID Icon,
Zafer Sezeri Department of Pharmacology, Medical Faculty, Erciyes University, Kayseri, TürkiyeORCID Iconhttps://orcid.org/0000-0003-4858-3906View further author information
ORCID Icon,
Aykut Ozdarendelij Vaccine Research, Development and Application Center, Erciyes University, Kayseri, Türkiye;k Department of Microbiology, Medical Faculty, Erciyes University, Kayseri, TürkiyeORCID Iconhttps://orcid.org/0000-0002-6950-8545View further author information
ORCID Icon,
Ates Karal Division of Pediatric Infectious Diseases, Department of Pediatrics, Hacettepe University, Ankara, Türkiye;m Head of Türkiye Vaccine Institute, Ankara, TürkiyeORCID Iconhttps://orcid.org/0000-0002-1654-3232View further author information
ORCID Icon &
Ihsan Atesg Department of Internal Medicine, University of Health Sciences Ankara City Hospital, Ankara, TürkiyeORCID Iconhttps://orcid.org/0000-0003-2858-6229View further author information
ORCID Icon show all
Article: 2122503 | Received 23 May 2022, Accepted 03 Sep 2022, Published online: 31 Oct 2022

References

  • Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, Pizarro A, Acevedo J, Leo K, Leon F, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):1–10. doi:10.1056/NEJMoa2107715.
  • Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–22. doi:10.1016/S0140-6736(21)01429-X.
  • Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–92. doi:10.1016/S1473-3099(20)30843-4.
  • Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11:585354. doi:10.3389/fimmu.2020.585354.
  • Genetic Engineering & Biotechnology News. Sinovac biotech – CoronaVac; 2020 May 18. [accessed 2021 Nov 29]. https://www.genengnews.com/covid-19-candidates/covid-19-keeping-an-eye-on/sinovac-biotech/.
  • Pavel STI, Yetiskin H, Uygut MA, Aslan AF, Aydın G, İ̇nan Ö, Kaplan B, Ozdarendeli A. Development of an inactivated vaccine against SARS CoV-2. Vaccines (Basel). 2021;9(11):1266. doi:10.3390/vaccines9111266.
  • Pavel STI, Yetiskin H, Aydin G, Holyavkin C, Uygut MA, Dursun ZB, Celik İ, Cevik C, Ozdarendeli A. Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey. PLoS One. 2020;15(9):e0238614. doi:10.1371/journal.pone.0238614.
  • Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45. doi:10.1001/jama.2021.8565.
  • Anand SP, Prévost J, Nayrac M, Beaudoin-Bussières G, Benlarbi M, Gasser R, Brassard N, Laumaea A, Gong SY, Bourassa C, et al. Longitudinal analysis of humoral immunity against SARS-CoV-2 spike in convalescent individuals up to 8 months post-symptom onset. Cell Rep Med. 2021;2(6):100290. doi:10.1016/j.xcrm.2021.100290.
  • Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384(1):80–82. doi:10.1056/NEJMc2032195.
  • Zinkernagel RM. On natural and artificial vaccinations. Annu Rev Immunol. 2003;21(1):515–46. doi:10.1146/annurev.immunol.21.120601.141045.
  • Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83–100. doi:10.1038/s41577-020-00479-7.
  • Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, Chu Y, Feng Y, Wang Q. Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. Clin Infect Dis. 2020;71(10):2688–94. doi:10.1093/cid/ciaa721.
  • Pavel STI, Yetiskin H, Aydin G, Holyavkin C, Uygut MA, Dursun ZB, Celik İ, Cevik C, Ozdarendeli A, Li K. Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkiye. PLoS One. 2020;15(9):e0238614. doi:10.1371/journal.pone.0238614.
  • Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, Yuan M, Leung WS, Chan JM, Chik TS, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020;25(16):2000421. doi:10.2807/1560-7917.ES.2020.25.16.2000421.
  • Reed LJ, Muench H. A simple method of estimating fifty percent end points. Am J Hyg. 1938;27:493–97. doi:10.1093/oxfordjournals.aje.a118408.
  • World Health Organization. Laboratory Procedures, Serological detection of avian influenza A(H7N9) infections by microneutralization assay; 2013 May 23. [accessed 2022 July 29]. https://www.who.int/publications/m/item/serological-detection-of-avian-influenza-a(h7n9)-infections-by-microneutralization-assay.
  • Lee YW, Lim SY, Lee JH, Lim JS, Kim M, Kwon S, Joo J, Kwak SH, Kim EO, Jung J, et al. Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. J Korean Med Sci. 2021;36(21):e153. doi:10.3346/jkms.2021.36.e153.
  • Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T cells in immunity to viruses. Nat Rev Immunol. 2012;12(2):136–48. doi:10.1038/nri3152.
  • Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, Nunna N, Huang W, Oestreicher J, Colpitts T, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021;27(11):2025–31. doi:10.1038/s41591-021-01527-y.
  • Brnjarchevska Blazhevska T, Babačić H, Sibinovska O, Dobrevski B, Kirijas M, Milanovski G, Arsov T, Petlichkovski A. A single dose of BNT162b2 vaccine elicits strong humoral response in SARS-CoV-2 seropositive individuals. Allergy. 2022;77(1):296–98. doi:10.1111/all.15047.
  • Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, Doolman R, Asraf K, Mendelson E, Ziv A, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84. doi:10.1056/NEJMoa2114583.
  • Kara A. Genel İmmünizasyon Prensipleri. Cocuk Enfeksiyon Dergisi 2(Supp 1) . 2008;3–14. [Article in Turkish].
  • Yue L, Xie T, Yang T, Zhou J, Chen H, Zhu H, Li H, Xiang H, Wang J, Yang H, et al. A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine. J Med Virol. 2022;94(1):35–38. doi:10.1002/jmv.27334.
  • Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
  • Pfizer quarterly corporate performance — second quarter 2021; 2021 July 28 [accessed 2021 Nov 29]. https://investors.pfizer.com/events-and-presentations/event-details/2021/Pfizer-Quarterly-Corporate-Performance–Second-Quarter-2021/default.aspx.
  • Lee HK, Knabl L, Knabl L, Kapferer S, Pateter B, Walter M, Furth PA, Hennighausen L. Robust immune response to the BNT162b mRNA vaccine in an elderly population vaccinated 15 months after recovery from COVID-19. medRxiv. 2021. Preprint 2021.09.08.21263284. doi:10.1101/2021.09.08.21263284.
  • Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol. 2022;94(1):39–41. doi:10.1002/jmv.27350.
  • Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, Mizrahi B, Alroy-Preis S, Ash N, Milo R, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393–400. doi:10.1056/NEJMoa2114255.
  • Lancet Infectious Diseases. COVID-19 vaccine equity and booster doses. Lancet Infect Dis. 2021;21(9):1193. doi:10.1016/S1473-3099(21)00486-2.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.